Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc., a Nevada corporation, on September 30, 2019, covering events occurring on September 25 and September 26, 2019. The Company is an emerging growth company with its principal executive offices in Framingham, Massachusetts. Its common stock and purchase warrants trade on The NASDAQ Stock Market LLC under the symbols "XBIO" and "XBIOW," respectively.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Roman Knyazev resigned as a member of the Board of Directors effective September 25, 2019. The resignation was not the result of any disagreement with the Company.
- Appointment: Grigory G. Borisenko, PhD, was appointed to the Board of Directors effective September 26, 2019, to fill the vacancy left by Mr. Knyazev.
- Committee Assignments: Mr. Borisenko was not appointed to any Board committees upon the commencement of his term.
Management Commentary and Compensation
Mr. Borisenko brings over 20 years of experience in the life sciences field, including roles as Investment Director at RUSNANO Management Company LLC and previous board service at Atea Pharmaceuticals, Inc. and Adastra Pharmaceuticals, Inc. He holds a Ph.D. from the Russian State Medical University and has co-authored over 50 peer-reviewed publications.
Regarding compensation, Mr. Borisenko will receive a cash retainer and be eligible for equity awards consistent with other non-management directors. The Company will enter into a letter agreement and a standard indemnification agreement with him. No other agreements or transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Key Facts for Investor Verification
- Confirm the effective dates of the director resignation (Sept 25, 2019) and appointment (Sept 26, 2019).
- Verify that the resignation of Roman Knyazev was not due to any disagreement with the Company.
- Review the specific terms of the cash retainer and equity award eligibility for Mr. Borisenko in subsequent filings or proxy statements.
- Note that Mr. Borisenko currently serves on the boards of two other biotechnology companies, which may present potential time commitment considerations.